Health
CARB-X funds Phico to develop new intravenous engineered bacteriophage drug – The Pharma Letter
Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop a new intravenous engineered bacteriophage drug to treat
Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop…To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
Or, if you’re only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO…
-
General21 hours agoSearch underway for missing boat off South Australia’s Cape Jaffa
-
Noosa News22 hours agoQueensland coroner investigates ‘extremely unusual’ deaths of premature twin boys
-
Noosa News23 hours agoChristmas tragedy: NSW woman dies after alleged deliberate hit-and-run on Sunshine Coast
-
Noosa News24 hours agoUpdate: Attempted murder charges, Maroochydore